•  
  •  
  •  
  •  

2026-03-26 07:24:25

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Avantel Ltd receives order worth Rs. 459.90 crores
  • Ceasefire Hopes Fuel Oil Slump and Equity Rally
  • BEL and RRP Group sign strategic MoU to advance collaboration in Semiconductor, Unmanned Systems and Electro-Optics
  • United Spirits Ltd divests its stake in Royal Challengers Sports Pvt Ltd for INR 166.6 bn
  • ACME Solar Holdings Ltd arm commissions 2nd phase of BESS project

Keywords Selected:  Injectable

Stock Report

  • Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes
  • Aptus Pharma Ltd to expand into life saving injectables and ICU care products
  • Closure of USFDA inspection at Zydus' Injectable plant at Ahmedabad
  • Alembic Pharmaceuticals Ltd receives 2 observations for Karakhadi Injectable Facility
  • Caplin acquires 10 approves ANDAs injection and Opthalmic products
  • Lupin receives EIR from US FDA for its Nagpur Injectable Facility
  • Caplin Point Laboratories Ltd's injectables facility completes INVIMA audit successfully
  • Zydus receives EIR for the injectable facility located at Jarod
  • Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
  • Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S.
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL
  • Lupin unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
  • Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Lupin receives 6 observations from USFDA for Nagpur Injectable facility
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe
  • Closure of USFDA inspection at Zydus' injectable manufacturing plant at Jarod
  • Lupin receives U.S. FDA approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity
  • Eris Lifesciences receives ANVISA approval for Sterile Injectable Facility
  • Lupin receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
  • Closure of USFDA inspection at Zydus' oncology injectable plant at Ahmedabad
  • Caplin Steriles Ltd gets USFDA approval for Phytonadione Injectable Emulsion
  • Lupin receives EIR from US FDA for its Injectable Facility in Nagpur
  • Concord Biotech Limited commences production of injectable at new facility

Latest Post

  • Avantel Ltd receives order worth Rs. 459.90 crores
  • Ceasefire Hopes Fuel Oil Slump and Equity Rally
  • BEL and RRP Group sign strategic MoU to advance collaboration in Semiconductor, Unmanned Systems and Electro-Optics
  • United Spirits Ltd divests its stake in Royal Challengers Sports Pvt Ltd for INR 166.6 bn
  • ACME Solar Holdings Ltd arm commissions 2nd phase of BESS project


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025